Article
ALCOA+ Contemporaneous Documentation — The Standard That Trips Companies
Of all the ALCOA+ principles, contemporaneous documentation is the one that generates the most Warning Letters — not because companies are falsifying records, but because decades of informal…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
ALCOA+ Contemporaneous Documentation — The Standard That Trips Companies
Of all the ALCOA+ principles, contemporaneous documentation is the one that generates the most Warning Letters — not because companies are falsifying records, but because decades of informal…
Article
3.2.P.6 Drug Product Reference Standards: Why the Same Program That Works for Drug Substance Often Falls Short for Drug Product
The cross-reference to 3.2.S.5 is not wrong. For the assay reference standard — the characterized primary standard used to quantify drug substance content in finished tablets, capsules, or…
Article
FDA 483 Production and Process Controls — The CMC Risk Map
Production and process controls 483 observations are the category where FDA's regulatory findings intersect most directly with your CMC submission — because the process controls FDA finds inadequate…
Article
Revlon Group Holdings Warning Letter: Component Testing and Laboratory Controls Failures and the CMC Pattern Every OTC Drug Quality Director Must Recognize
On June 2, 2026, FDA issued Warning Letter 320-26-89 to Revlon Group Holdings, LLC at its Oxford, North Carolina facility — a registered OTC drug product manufacturer —…
Article
Huons Co. Warning Letter: Data Integrity and the CMC Pattern Every Sterile Products Quality Director Must Recognize
On June 15, 2026, FDA issued Warning Letter 320-26-95 to Huons Co., Ltd., a drug manufacturing facility located at 100 Bio Valley-ro, Jecheon, Chungcheongbuk, South Korea, citing systemic…
Article
3.2.P.5.4–5.6 Batch Analyses, Drug Product Impurities, and Justification of Specification: Closing the Evidence Loop
Sections 3.2.P.5.4, 5.5, and 5.6 are where the drug product specification is tested against reality. The batch analysis data must demonstrate that the process reliably meets the specification;…
Article
FDA 483 Equipment and Facilities — What Inspectors Actually Document
FDA equipment and facilities 483 observations are rarely about whether the equipment works — they are almost always about whether the documentation demonstrates that the equipment has been…
Article
3.2.P.5.1–5.3 Drug Product Specifications, Analytical Methods, and Validation: The Testing Architecture FDA Reviews Most Critically
The drug product specification is not complete because it passes internal review. It is complete when it addresses every critical quality attribute identified in P.2, when every method…
Article
FDA 483 Laboratory Controls — Deep Dive for CMC Scientists
Laboratory controls 483 observations are the most frequently issued citation category in FDA drug manufacturing inspections — and they are almost always rooted in the same two failures:…
Article
3.2.P.4 Control of Excipients: Risk-Based Qualification That Goes Beyond Compendial Compliance
"The answer 'the excipient complies with USP/EP' satisfies the basic identification and quality requirement in 3.2.P.4 — and it is the answer that generates the follow-up deficiency 'please…
Article
Sante Manufacturing Inc. Warning Letter: Raw Material Identity and Supplier Qualification Failures and the CMC Pattern Every OTC Drug Quality Director Must Recognize
On June 5, 2026, FDA issued Warning Letter 320-26-94 to Sante Manufacturing Inc., an over-the-counter drug product manufacturer located at 516 John Street N, Aylmer, Ontario, Canada. The…
Article
3.2.P.3 Drug Product Manufacture: Batch Formula, Process Description, and Validation Evidence That Survives FDA Review
The most common manufacturing-related CMC information request FDA issues for drug product applications is not about batch failure — it is about the gap between the process description…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.